These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 12483729

  • 1. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
    Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group.
    Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
    [Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
    Davis JC, Totoritis MC, Rosenberg J, Sklenar TA, Wofsy D.
    J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
    [Abstract] [Full Text] [Related]

  • 3. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM, Lan JL, Lin HY, Luo SF.
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [Abstract] [Full Text] [Related]

  • 4. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, Weisman MH.
    Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS.
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [Abstract] [Full Text] [Related]

  • 7. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW, Gordon R, Hsu B.
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [Abstract] [Full Text] [Related]

  • 8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 9. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR, Sato EI.
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [Abstract] [Full Text] [Related]

  • 10. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI, Robbie G, Levin R, Berney SM, Chindalore V, Olsen N, Richman L, Le C, Jallal B, White B, Lupus Interferon Skin Activity (LISA) Study Investigators.
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [Abstract] [Full Text] [Related]

  • 11. Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial.
    Abdou NI, Rider V, Greenwell C, Li X, Kimler BF.
    J Rheumatol; 2008 May; 35(5):797. PubMed ID: 18381791
    [Abstract] [Full Text] [Related]

  • 12. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 13. Menopause hormonal therapy in women with systemic lupus erythematosus.
    Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, Lara-Reyes P, Jiménez-Santana L, Romero-Díaz J, Cravioto MD.
    Arthritis Rheum; 2007 Sep; 56(9):3070-9. PubMed ID: 17763408
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 15. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS, Pereira FV, de Sá MF, Paulo LJ, Martins WP, Ferriani RA.
    Maturitas; 2009 Mar 20; 62(3):311-6. PubMed ID: 19193505
    [Abstract] [Full Text] [Related]

  • 16. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE, GL601 Study Group.
    Arthritis Rheum; 2002 Jul 20; 46(7):1820-9. PubMed ID: 12124866
    [Abstract] [Full Text] [Related]

  • 17. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
    Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM.
    Arthritis Rheum; 2002 Mar 20; 46(3):755-65. PubMed ID: 11920412
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun 20; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug 20; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

  • 20. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.
    Arthritis Rheum; 2004 Sep 20; 50(9):2858-68. PubMed ID: 15452837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.